Aclaris Therapeutics (ACRS) vs Arvinas (ARVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Arvinas (ARVN) over the past year, gaining 99.5% versus a loss of 23.0%. Over five years, ACRS leads with a -77.5% price change compared with -91.2% for ARVN. Aclaris Therapeutics is the larger company by market cap ($561.6 million vs $495.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | ARVN |
|---|---|---|
| Share price | $3.82 | $7.69 |
| Market cap | $561.56M | $495.85M |
| 1-day change | +0.66% | +2.33% |
| YTD return | +25.91% | -36.68% |
| 1-year return | +99.47% | -22.97% |
| 5-year return | -77.45% | -91.18% |
| P/E ratio (TTM) | — | 29.56 |
| EPS (TTM) | $-0.58 | $0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $14.51 |
| 52-week low | $1.74 | $6.97 |
| Distance from 52-week high | -42.20% | -47.04% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +166.84% | +81.26% |
| Average volume | 2.59M | 788.21K |
| Shares outstanding | 147.20M | 64.52M |
| Employees | 69 | 246 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed ARVN by 122.4 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
ACRS vs ARVN FAQ
Which is bigger, Aclaris Therapeutics or Arvinas?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $561.56M compared with $495.85M for Arvinas (ARVN).
Which stock has performed better over the past year, ACRS or ARVN?
ACRS returned +99.47% over the past 12 months, compared with -22.97% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Arvinas in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.